France Archives

News and Trends 3 Oct 2014

A new way to develop therapeutic monoclonal antibodies against Cancer

Up to now, a vast majority of antibodies targets proteins. Why not targeting something else? ImmuSmol, a start-up based in Bordeaux South of France is developing monoclonal antibodies against small molecules involved in tumor immune escape. This French start-up has just raised €500k to complete its preclinical proof-of-concept. Bordeaux is one of the biggest wine […]

October 3, 2014 - 2 minutesmins - By Philip Hemme

Carmat polemic intelligent artificial heart

News and Trends 24 Sep 2014

The Polemic of First Intelligent Artificial Heart

The first intelligent artificial heart has been twice implanted in France within clinical trials. It has been developed by French company Carmat, and famous cardiologist Alain Carpentier, after 20 years of development. This important breakthrough nevertheless create a polemic. Artificial hearts already existed and voice talks about an artificial financial bubble around Carmat. On September 11th, […]

September 24, 2014 - 4 minutesmins - By Joachim Eeckhout

News and Trends 3 Sep 2014

EMA give Orphan Drug Designation to the CER-001 of Cerenis

Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular disease, announced today that it has received two separate Orphan Drug Designations from the European Medicines Agency (EMA) for the use of CER-001 in the treatment of patients with rare genetic defects in HDL synthesis/maturation pathways, […]

September 3, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 31 Aug 2014

Why should you drink tea instead of coffee?

Drinking tea reduces non-cardiovascular mortality by 24%, reveals a study in 131 000 people presented at ESC Congress today by Professor Nicolas Danchin from France. Professor Danchin said: “If you have to choose between tea or coffee it’s probably better to drink tea. Coffee and tea are important components of our way of life. Their […]

August 31, 2014 - 4 minutesmins - By Julie Lellouche

News and Trends 26 Aug 2014

Adocia launches a Phase III in India for its Diabetic Foot Ulcer treatment

Adocia announced today the initiation of a clinical Phase III study in India of BioChaperone PDGF-BB, the company’s innovative formulation of Platelet Derived Growth Factor (PDGF-BB) for the treatment of diabetic foot ulcers. This follows the approval given by the Drug Controller General of India (DCGI) on August 22nd, 2014. The dossier for this clinical […]

August 26, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 19 Aug 2014

Sanofi buy Mannkind’s inhaled insulin for $925m

Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter […]

August 19, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 19 May 2014

Discover Hello Tomorrow Challenge, European largest technological start-up challenge

I was lucky to be invited as a media partner for the first edition of Hello Tomorrow Challenge (HTC) on April 18 at the Museum of Science and Industry in Paris. Technological innovations of the future were highlighted and rewarded by over 400k€. The event gathered over 1,200 attendees and focused on five major areas that […]

May 19, 2014 - 3 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us